Monthly Archives: March 2020

China Hawks Are Calling the Coronavirus a Wake-Up Call – The Atlantic

Posted: March 11, 2020 at 3:45 pm

Trump has yet to adopt all these policies. But the fallout from the global outbreak, which coincides with his reelection bid, could motivate him to do so. Coronavirus is the intersection of 3 issues @realDonaldTrump has been right about all along: border control, American manufacturing, China hawk, Donald Trump Jr. tweeted recently, in a preview of a possible campaign message.

Read: The strongest evidence yet that America is botching coronavirus testing

And, if implemented, such policies could upend global supply chains and renew a push to unwind economic integration between the worlds two largest economies, which could significantly reverse globalization. (This had slowed somewhat after the U.S. and China struck an interim trade agreement in January.) Globalism, with its unwieldy and complex systems tied to yet more complex systems, could be the biggest casualty in the war on the coronavirus, Curtis Ellis, the policy director of America First Policies, the nonprofit arm of a pro-Trump super PAC, wrote last month.

These arguments have been echoed by China hard-liners in Congress. In response to the coronavirus outbreak, Rubio and another Republican senator, Josh Hawley, have proposed separate bills to lessen Americas reliance on China for medical supplies. Whether the administration will support these initiatives isnt clear. During a congressional hearing last month, Health and Human Services Secretary Alex Azar said he shared Rubios concern about Americas reliance on China for active pharmaceutical ingredients. Yet he cautioned that disentangling globalized supply chains in favor of domestic manufacturing cant be accomplished overnight and could raise health-care costs for Americans.

Rubio has previously warned of the risks that China poses to the U.S. health-care industry and challenged Beijing on numerous issues, including its efforts to suppress pro-democracy protests in Hong Kong. He told me that the depletion of Americas manufacturing sector has left us with a huge national-security vulnerability, necessitating a 21st-century, pro-American industrial policy.

The bids to break free from Americas bonds with Beijing, moreover, go well beyond the medical sector. Mac Thornberry, the ranking Republican member of the House Armed Services Committee, has stated that while we want to get coronavirus contained [and] eliminated as fast as we can maybe we can also take this opportunity to reduce Americas reliance on China for defense-related products and components.

When I asked Rubio why he was taking a more confrontational approach to China during a global emergency that seemed to call for international cooperation, he maintained that the Chinese Communist Party has proven it is not a reliable or responsible global power.

China impeded efforts of international researchers and failed to share information on the source of the virus or best practices, he said. Their Communist Party is more interested in saving face and stamping out internal dissent [than] in helping [to] prevent the spread of [this] dangerous disease.

Read more from the original source:

China Hawks Are Calling the Coronavirus a Wake-Up Call - The Atlantic

Posted in Donald Trump | Comments Off on China Hawks Are Calling the Coronavirus a Wake-Up Call – The Atlantic

Donald Trump Junior Urges US Troop Withdrawal from Kosovo – Balkan Insight

Posted: at 3:45 pm

Donald Trump Jr. Photo: EPA/FRANCIS R. MALASIG

Donald Trump Jr wrote on Twitter on Tuesday that he agrees with a suggestion by Republican senator David Perdue that the US should reconsider its presence in Kosovo if Pristina does not agree to fully revoke its 100 per cent tariffs on imports from Serbia.

There are 650 US troops in Kosovo. Time to get them home, said Trump Jr, who holds no official position in the US administration but is executive vice-president of his fathers Trump Organisation.

Senator Perdues comments stepped up the pressure on the Pristina authorities over the tariffs.

For over two decades, US forces have helped keep the peace between Kosovo & Serbia. Now, with historic progress in sight, Kosovo must do its part & abolish all duties imposed on Serbia. If Kosovo is not fully committed to peace, then the US should reconsider its presence there, Perdue wrote on Twitter.

Significantly for Kosovo politicians, Perdues message was retweeted by Trumps envoy for Kosovo-Serbia peace negotiations, Richard Grenell.

Grenell warned last week after Kosovos Prime Minister Albin Kurti said the tariffs on imports of Serbian products would only be gradually removed that the US would not waste our assistance if Kosovos leadership kept harming its people this way.

Kurtis proposal has not yet been agreed with his Vetevendosje (Self-Determination) partys junior governing partners, the Democratic League of Kosovo. The proposal has been dismissed by Serbia as a fraudulent and dishonest.

Suggestions that the US military could possibly pull out of Kosovo have sparked alarm among some politicians in the country.

President Hashim Thaci on Tuesday urged Kurtis government to call an emergency session to lift the tariffs. Thaci wrote on Facebook that the future of our country is in question.

The leader of the Democratic League of Kosovo, Isa Mustafa, sent his envoy Skender Hyseni to talk to Grenell about the issue.

After the talks, Hyseni said that he was told that Kosovo must find a solution or risk further tension with the US.

The White House and ambassador Grenell strongly urge the immediate and unconditional lifting of tariffs on goods from Serbia to pave the way for a Kosovo-Serbia dialogue that should and will be concluded with mutual recognition, Hyseni wrote on Facebook.

He said that he was told by Grenell that America cannot continue to spend hundreds of millions of dollars on military and other aid and projects in a place where the government works against the interests of its citizens.

US troops have been in Kosovo as part of NATOs KFOR peacekeeping mission since the war ended 1999.

Excerpt from:

Donald Trump Junior Urges US Troop Withdrawal from Kosovo - Balkan Insight

Posted in Donald Trump | Comments Off on Donald Trump Junior Urges US Troop Withdrawal from Kosovo – Balkan Insight

The Ticket: Beating Donald Trump, With David Plouffe – The Atlantic

Posted: at 3:45 pm

David Plouffe got it very wrong in 2016.

After confidently predicting Donald Trumps defeat, the campaign manager credited with Barack Obamas historic 2008 victory watched a reality-television star become commander in chief. Four years later, Plouffe says he rewatched that Election Night. Over and over.

And after absorbing the lessons of that day, hes written a book on what Democrats need to do to defeat Trumpa reelection battle that, as he told Edward-Isaac Dovere on the latest episode of The Ticket: Politics From The Atlantic, probably has the biggest stakes the countrys ever known. They discuss the presidents reelection campaign, the state of the Democratic Party, and a nomination fight thats suddenly become a two-man race.

Listen to the full episode here:

Subscribe to The Ticket: Apple Podcasts | Spotify | Stitcher (How to Listen)

Several Highlights

Voices

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

Go here to read the rest:

The Ticket: Beating Donald Trump, With David Plouffe - The Atlantic

Posted in Donald Trump | Comments Off on The Ticket: Beating Donald Trump, With David Plouffe – The Atlantic

Donald Trumps toolkit – The Economist

Posted: at 3:45 pm

Mar 7th 2020

WASHINGTON, DC

AMERICAS GOVERNMENT, as all its citizens learn at school, comprises three branches: executive, legislative and judicial. At the top of the executive branch sits the actual executivethe president. But the branch also includes an array of agencies, both the departments represented in the cabinet, and othersincluding the National Security Council and the Council of Economic Advisersthat make up the Executive Office of the President (EOP). These agencies advise on and implement presidential policy. Most of the EOP gets repopulated with a change in administration, as it should: new presidents have new policy agendas, which require new personnel.

The exception to that rule is the EOPs biggest office: the Office of Management and Budget (OMB). Most of its 500-odd employees are career civil servants who take pride in providing nonpartisan advice to presidents of both parties. In 1921 Charles Dawes, the first head of the OMBs predecessor agency, the Bureau of the Budget, explained that if Congress passed a law that garbage should be put on the White House steps, it would be our regrettable duty, as a bureau, in an impartial, nonpolitical and nonpartisan way, to advise the executive and Congress as to how the largest amount of garbage could be spread in the most expeditious and economical manner. Russell Vought, the OMBs acting director, calls his office the presidents Swiss army knife. It has been central to Donald Trumps efforts to loosen environmental regulations and to cut budgets. It also played a role in the Ukraine scandal.

When Congress refused to appropriate adequate funds for Mr Trumps border wall, OMB found it. When the government shut down in 2018-19, the OMB found ways for the Internal Revenue Service to send out tax refunds, and for the Department of Agriculture to provide food stamps. The OMBs job is to understand the mechanics of federal-government operations, and explain to the president and his staff how to get things done. Its titular head is Mick Mulvaney, who is also the presidents chief of staff, but Mr Vought, a former Hill staffer and vice-president of Heritage Action, a conservative policy-advocacy group, has operational control.

The OMB staff often have backgrounds in law or public policy, and tend to like their work: for the past five years, the OMB has ranked in the top quartile of small federal agencies in the Partnership for Public Services Best Places to Work in the Federal Government survey. (It had dipped early in the Obama administration; Peter Orszag, Mr Obamas first OMB director, was widely disliked.) One senior official in a previous administration praised the offices civil servants: I thought they were just so good, so knowledgeable. They were stubbornish about making clear what they thought, but they also did a lot of, Well, if you want to do that stupid thing, heres how you do it.

As the B in the offices name suggests, one of OMBs chief duties is to write the presidents annual budget, in consultation with agencies from across the federal government. Because Congress, not the executive, appropriates funds, the presidents budget is an expression of wishes, not an allocation of funds. To translate the presidents policy priorities into budgetary terms, the OMBs Resource Management Offices (RMOs), organised by broad oversight areas, weigh competing interests from different parts of government. For the Trump administration, that meant proposing a 27% cut in the funding of the Environmental Protection Agency and a 21% cut in the State Department this year.

Another duty, as the M suggests, is managerial. Once a budget passesor, as has grown increasingly common, there is a continuing resolution, that merely keeps current funding levels constantthe OMB advises and evaluates agency performance. The OMB also oversees a range of federal functions, including procurement, IT, personnel and financial management.

Within the OMB sits the Office of Information and Regulatory Affairs (OIRA). OIRA reviews agencies proposed regulatory changes, ensuring that benefits outweigh costs, and, for new regulations, that agencies have fully considered non-regulatory alternatives to achieve their stated goals.

OIRA has been central to Mr Trumps deregulatory effort. Just days after his inauguration, the president issued an executive order requiring two regulations to be repealed for every new one introduced. In October his administration estimated that it had actually cut eight and a half regulations for every new one. Some take issue with how Mr Trumps OIRA conducts cost-benefit analysis of these regulations. Richard Revesz of NYU Law School argues that in its deregulatory zeal, the Trump administration has made a mockery of cost-benefit analysis [by] weighing broader indirect costs [of regulation], and insisting on ignoring any indirect benefits. In delaying Obama-era environmental regulations, for instance, he argues that the administration has ignored or downplayed unquantified benefits, such as long-term improvements to air and water quality, while overstating the costs of compliance to industry.

In its keenness to deregulate, OIRA has sometimes got in its own way. According to the Institute for Policy Integrity, a think-tank, the administration has won just five of the 71 court challenges it has faced over deregulation and other agency policy.

Although Mr Vought says morale at the OMB remains healthy, one recently retired veteran demurs. Career staff were asked [] give us options to do X. They would lay out a range of options, including ones they thought would be extreme enough to be a non-starter, and usually they chose the non-starter. The department has also become unusually high-profile for the wrong reasons: it was the OMBs associate director for national security programmes, Michael Duffey, who told the Pentagon that there was clear direction from POTUS to continue to hold military aid to Ukraine.

In January the Government Accountability Office (GAO), a non-partisan auditor, found that this action violated federal law. Mr Vought disputes that: he believes that the OMB had the right to delay funding, and that the GAOs analysis stems partly from partisan animus (the GAO answers to Congress rather than the president). He also notes that the White House has delayed other tranches of foreign aid, such as to Pakistan and Gaza, over policy concerns.

When not getting rid of regulations and holding up military aid to allies, the OMB has been doing the sort of good-government things it might have done under any administration, streamlining the federal grantmaking process or implementing a law which encourages government to use data better when drafting policy. Another ex-employee says he is impressed with peoples ability to continue to do their job even when the interest in a fair process isnt being respected by the leadership of the administration. Which is about as pejorative as a retired civil servant can be.

Dig deeper:

This article appeared in the United States section of the print edition under the headline "The toolkit"

See the article here:

Donald Trumps toolkit - The Economist

Posted in Donald Trump | Comments Off on Donald Trumps toolkit – The Economist

GOP Group Hits Donald Trump With Supercut Of His Offensive, Ridiculous Statements – HuffPost

Posted: at 3:45 pm

The Lincoln Project a group of anti-Trump Republicans on Friday hit the president with a montage of his most insulting, offensive and ridiculous gaffes.

The group of which prominent Trump critic George Conway is a member released the supercut that contrasts Trumps speeches to those of previous presidents in response to a similar GOP attack on Democratic presidential candidate Joe Biden over his own gaffes.

Every day is a new chance for Trump to debase himself further and embarrass Americans of all political stripes, Republican strategist Rick Wilson wrote in a fundraising email featuring the footage.

Check out the video here:

Wilson said the hardest part of making the ad was fitting all of Trumps own gaffes, abuse of the English language, insults, lies and crazy talk into 30 or even 60 seconds.

We will not allow Trump and his propaganda machine to gaslight America into believing hes anything other than the most unserious, indecent, least inspiring president weve ever had, he concluded. Do not let a single lie stand.

Continue reading here:

GOP Group Hits Donald Trump With Supercut Of His Offensive, Ridiculous Statements - HuffPost

Posted in Donald Trump | Comments Off on GOP Group Hits Donald Trump With Supercut Of His Offensive, Ridiculous Statements – HuffPost

Opinion: Sleepy Joe Biden has given Donald Trump a wake-up call – The Globe and Mail

Posted: at 3:45 pm

Niall Ferguson is the Milbank Family senior fellow at the Hoover Institution, Stanford

I know Joe Biden. Not well, but well enough to have a good chat when we ran into one another at the Irish embassy in Washington on St. Patricks Day last year. I must also confess to rather liking Mr. Biden. In 2015, I argued that he would win if he ran the next year.

Yet, in 2020, there has been something about his campaign that has been, well, off. One example: He was speaking last Monday at a campaign event in Texas. The crowd was fired up; their man had been on a roll since winning South Carolina two days earlier. And this is what he said: We hold these truths to be self-evident. All men and women are ... created by the ... go ... you know, you know, the thing.

Story continues below advertisement

I hope you dont need me to tell you that Thomas Jeffersons preamble to the declaration of independence is a little more eloquent than that.

Earlier this year, The Atlantic ran a sympathetic story about Mr. Bidens boyhood stutter, suggesting that this was the reason for his verbal stumbles although Mr. Biden himself kept telling the author that this wasnt the problem.

Mr. Biden is 77 years old and it really, really shows which only adds to the mystery of his political comeback. Prior to his victory in South Carolina on Feb. 29, Mr. Biden appeared to be out of it in both senses. By Wednesday morning, he was back where he began last year: the front-runner. Not only did Pete Buttigieg and Amy Klobuchar drop out last week, but they promptly pledged their support to Mr. Biden. Most recently, former Democratic hopefuls Kamala Harris and Cory Booker have endorsed the former vice-president.

There have been primary comebacks before; indeed, an election year is incomplete without at least one. I remember vividly, as one of John McCains advisers in 2008, glumly anticipating his exit from the race only for his almost-broke campaign to turn around and propel him to the nomination after he won New Hampshire. It was that same state that made Bill Clinton the comeback kid in 1992.

But Mr. Biden lost New Hampshire, finishing in ignominious fifth place. To find a comeback this late in the game, you need to go back to the 1996 Republican nomination contest, when veteran Kansas senator Bob Dole went into the South Carolina primary having lost three states to the conservative firebrand Pat Buchanan.

The kingmaker then was Carroll Campbell, the states popular Republican governor. Just as House majority whip and South Carolina representative Jim Clyburn did for Mr. Biden, Mr. Campbell went all in for Mr. Dole, signalling to the voters in the state and nationally that he alone had a shot at beating the incumbent president. Mr. Dole won South Carolina easily, after which he won every remaining contest with the exception of the Missouri caucuses.

Of course, Mr. Dole went on to lose to Bill Clinton, so this is an analogy Mr. Biden would probably prefer to have a senior moment about. Yet, I am not so sure he would lose to Donald Trump if nominated.

Story continues below advertisement

The other key take away from last week is that the majority of black voters backed Mr. Biden last week and not just in South Carolina. As the brilliant African-American writer Coleman Hughes tweeted: The fact that black voters went overwhelming for Biden is only surprising if youre unaware that black dem voters are way more conservative than white dem voters. The progressive activist class may feel itself to be channeling black Americas politics, but its not.

In the coming months, the virulence and lethality of COVID-19 will almost certainly matter more than Mr. Bidens charm and incoherence. A large outbreak in a U.S. state and/or a recession caused by the global shock of the potential pandemic could make Mr. Trump a one-term President.

St. Patricks Day is nine days away. If the luck of the Irish holds, Mr. Trump is about to be hit by a cross between Hurricane Katrina and Lehman Brothers, and the man he derides as Sleepy Joe will duly oust him from the White House.

And if COVID-19 hits only the Democratic states of the coasts? If the economy stalls for a quarter but doesnt crash? If the message sticks in the Midwest that the epidemic was a hoax? Then I fear we are in for one of the least intelligible concession speeches in you know, the thing.

Joe Biden hopes to take a big step toward the Democratic presidential nomination on Tuesday when six states cast votes, while Bernie Sanders aims for an upset win in Michigan that would keep his White House hopes alive. Reuters

Niall Ferguson/The Sunday Times, London.

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

Here is the original post:

Opinion: Sleepy Joe Biden has given Donald Trump a wake-up call - The Globe and Mail

Posted in Donald Trump | Comments Off on Opinion: Sleepy Joe Biden has given Donald Trump a wake-up call – The Globe and Mail

Between Real Estate And Science Fiction: Cities Of Immortals – Forbes

Posted: at 3:44 pm

The ongoing biotechnology revolution is less discussed than the digital one, but is on par with it, if not more prevalent. While less visible to the everyday eye, progress in healthcare and genetics will dramatically alter the way and where we live. Indeed, it feels like science fiction has crept into reality.

For some time now, it has been possible to create an embryonic precursor from someones blood cells. Essentially, this means that scientists can recreate a younger you in the form of an unevolved and unaged specimen, which could eventually turn into a fetus that will grow into an adult, with your DNA. Some scientists are suggesting that DNA doesnt age much; what does is the epigenetic, or the molecular processes that regulate the expressions of DNA.

Nowadays, a growing scientific movement views aging not as a consequence of growing older, but as a condition in and of itself, a pathology. In other words, aging is a disease that is not a result of a degradation of DNA, but of the epigenetic. Once we understand how to reboot it and restore the functioning of DNA, we could have treatments for aging and perhaps even the possibility to reverse it.

Highly controversial, of course. Nevertheless, we are slowly but surely moving toward dramatically extending human longevity and eventually, towardcellular regeneration (i.e., regrowing limbs).

There are substantial investments being made with this goal in mind, and results will be obtained much faster than we are aware. As an example, in the 1990s, gene therapy was perceived as high-risk and elusive. Today, a group of technologies named CRISPR-Cas9 enables scientists to edit genomes and alter DNA sequences, with the potential to correct genetic diseases and cure cancer.We may even be able to create immortality. Scientists have not yet found how to do it, but at some point, they well could.

Think of the luminaries the world lost early, of diseases or from causes that genetics research seeks to cure. Steve Jobs lived to be 56. He died as Apple just started really growing exponentially in a business sense, and in creativity benefiting from his decades of experience.

Zaha Hadid, the first woman to win the Pritzker prize (considered the Nobel prize for architects) died in 2016 at age 65. She really began to be at the top of her field after 2000, or age 50. Considering that she still might have had her best years ahead, advances in longevity could have an enormously positive effect on our cities, if world-class architects and real estate developers are able to exponentially leverage their experience for longer. Good news.

Urbanism is turning into one of the worlds most pressing issues. Desirable cities are so unaffordable that housing negatively impairs national GDP growth by several points. And well-planned architecture has been found to reduce crime. Boosting longevity could have a direct correlation with much faster economic growth and lower crime. And immortality, all the more. All in all, as human progress accelerates, so should that of our cities and lifestyles.

Living longer would indeed drastically affect the demographic makeup of our cities. With the nationwide trend of migration back toward cities, downtowns have again become gravity centers as jobs, social life and opportunities are all located next to one another. In other words, cities are becoming harder to leave. As their inhabitants have children, grandchildren and great-grandchildren, and live longer, the populations of cities like New York could explode. And so could real estate prices, by the sheer force of supply and demand not to mention that the older the population grows, the higher the amount of savings in the economy, hence additional capital increasing housing prices.

There urgently need to be solutions. Just based on migration trends, nearly 70% of the worlds population will live in cities in 2050. (That number is over 54% today, and was 34% in 1960.)

One solution could be a movement that is already making a comeback in todays world: multigenerational housing, through which several generations of a same family coexist under the same roof. Would the United States then become more like traditional Europe, where close-knit families often live together for decades into adulthood? The potential societal changes are enormous. Cities would, in this case, revert to what they had always been before: homes for whole families, as opposed to, say, downtowns of solely high-earning young professionals.

Additionally, advances in transportation such as ride-sharing will reduce the need to own our own cars. If we need fewer roads, we will have more space to build probably taller, if the aforementioned experts live longer and are able to develop the appropriate real estate structures. There's another factor increasing urban density.

And what about zoning? If we know we will live until 150, will we take a different outlook at community board meetings, and be more open to rezonings to allow the additional housing that enables our family members to stay close to us? Longevity could lead to less friction on hot-button local issues.

The science fiction of longevity and immortality is much closer to reality than we think. It should be embraced, as it features the potential to drastically improve the way we live together. Optimism is de rigueur for one of the planets most challenging and divisive issues. Public policy must follow and allow cities to shape themselves and grow in a way that retains all this means allowing sound, large-scale construction and urbanism.

Go here to read the rest:
Between Real Estate And Science Fiction: Cities Of Immortals - Forbes

Posted in Human Longevity | Comments Off on Between Real Estate And Science Fiction: Cities Of Immortals – Forbes

What Jason Hope Says About New Longevity Research – HealthTechZone

Posted: at 3:44 pm

Throughout the past decade, various topics related to stem cells have made headlines across all platforms. From being hailed as the most innovative method for eradicating specific diseases, to being protested by various groups and organizations, the use of stem cells has gained national attention repeatedly. With promising initial scientific findings, and avid researchers aiming to solidify the presence of stem cell usage in the realm of science on a normalized basis, increasing numbers of startups, biotech giants, and independent companies are forging ahead with stem cell-related projects. As global connectivity, technological advancements, and the marriage between medicine and technology continues to evolve swiftly, Jason Hope sees stem cells will undoubtedly remaining in the spotlight.

Over 20 years ago, scientists successfully extracted the first human embryonic stem cells, and effectively grew these cells in a lab setting. The remarkable feat of being able to successfully grow the parent cells, which essentially allow for the growth of new cells in the body, was a hopeful moment for the medical sector involved in creating effective regenerative treatments for conditions like heart disease, Alzheimers, stroke, and Parkinsons Disease. Using basic reasoning, the successful regeneration of parent cells could provide the regeneration of undesired cells, leading to anti-aging results, or effective care for many age-related conditions that deteriorate the body over time.

Though this initial breakthrough was promising, the scientific community has not yet made significant strides in bringing stem cell therapy to market in a way that is well-researched, backed by medical associations, and commonly accepted by the scientific community. In fact, the only readily utilized stem cell treatments are related to successfully growing blood cells from matching donors for patients with various blood disorders. According to entrepreneur, philanthropist, and expert in the realm of anti-aging and longevity, Jason Hope, these initial utilization of stem cells are commendable, but require a lot more research in order to maximize the potential widespread benefits of stem cells in medicine.

Hope, who has devoted much of his philanthropic endeavors within the medical industry via groups like the SENS Organization, recognizes that most stem cell implementations are rightfully considered experimental until appropriate research, testing, and development can occur. As an expert in the realm of anti-aging, and the championing of increasing health throughout a lifetime, Jason Hope recognizes the potential distrust that can be formulated by the general public as a result of eager companies making lofty claims or promoting potentially faulty treatments not yet fully vetted by the medical community. Thus, while he remains avidly enthralled by the potential maximization of stem cell therapies, hope supports the long-term research needed to safely, successfully, and effectively generate breakthrough stem cell treatments.

Providing continued backing for the extensive research completed at the SENS (Strategies for Engineered Negligible Senescence) Organization, Hopes contributions aid in the research aiming to create preventative treatments for degenerative diseases and utilizing breakthrough science to increase the overall long-term quality of life for individuals. Instead of focusing on the treatment of symptoms and the disease throughout the progression of the condition, the scientists at SENS work to examine ways to successfully prevent the disease from happening. Through this boundary-pushing work, a lot of their research focuses on stem cell intervention. According to Hope, stem cell treatments for Parkinsons Disease are now in the second stage of clinical trials at SENS. While the process of undergoing such extensive trials may appear slow, it is crucial to maintaining overall public support via successful treatment launches and promising in terms of the long-term possibilities linked to stem cell treatments.

In addition to the research being conducted by SENS, preliminary medical studies are being conducted with a myriad of uses for stem cells. Experimental stem cell transplants of retinal cells were recently utilized in a small research study of macular generation, providing initially promising results for the handful of patients who have received artificially generated retinal cells. Elsewhere, scientists have begun to explore ways to minimize potential rejection of stem cells in organs like the liver, through maximizing the most conducive environment for stem cells to thrive. While these slow-moving vehicles of change are less prominent than startups promising the proverbial Fountain of Youth via experimental stem cell treatments, these medically sound research studies are forming the backbone of stem cell treatment for the future.

As with all scientific and medical innovations, Hope also recognizes the potential risks, hurdles, and roadblocks within the growing field of stem cell research, and integration into medicine. From supply chain concerns to potential long-term side effects, and the risk of overly eager startups making too-lofty claims, Hope understands that the road to the everyday utilization of stem cells remains lengthy and potentially bumpy. However, the proverbial juice may very well be worth the squeeze in this example. As stem cells harvest the potential power to overturn the degenerative effects of some of the most prominent diseases, allow individuals to maintain active health for elongated periods of time, and increase the quality of life for countless individuals, expanding upon the initial promising research is potentially a pivotal point for the medical community and humankind. Though the road to successful scientific integration of stem cells is long, the potential healthcare benefits are limitless, and according to industry experts like Jason Hope, worth investing in, exploring, and championing.

About Jason Hope

An avid entrepreneur, investor, and philanthropist, Jason Hope is a futurist involved in the championing of technological advancement, community involvement, and innovative medical interventions. Deeply passionate about the anti-aging, longevity, and human advancement niche of biomedicine, Hope remains actively involved in various scientific organizations.

After receiving a degree in Finance from ASU, and a subsequent MBA from ASUs W.P. Carey School of Business, Hope developed a successful mobile communications company. Professionally, he currently focuses on investing in startups and developing grant programs for small businesses.

Follow Jason Hope:

LinkedIn | Facebook | Twitter | Medium

Continue reading here:
What Jason Hope Says About New Longevity Research - HealthTechZone

Posted in Human Longevity | Comments Off on What Jason Hope Says About New Longevity Research – HealthTechZone

Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights – Kentucky Journal 24

Posted: at 3:44 pm

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Get Sample Copy Of The Report@https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Request For Report Discount@https://www.trendsmarketresearch.com/report/discount/11698

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Report Analysis@https://www.trendsmarketresearch.com/report/analysis/BCC/global-longevity-and-anti-senescence-therapy-market

Go here to see the original:
Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights - Kentucky Journal 24

Posted in Human Longevity | Comments Off on Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights – Kentucky Journal 24

The Global Precision Medicine Software Market is expected to grow by USD 882.65 mn during 2020-2024, progressing at a CAGR of 11% during the forecast…

Posted: at 3:44 pm

New York, March 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Software Market 2020-2024" - https://www.reportlinker.com/p05873485/?utm_source=GNW Our reports on global precision medicine software market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by benefits of precision medicine.In addition, digitization of healthcare is anticipated to boost the growth of the global precision medicine software market as well.

Market Segmentation The global precision medicine software market is segmented as below: Delivery Mode: On-premise

Cloud-based

Geographic Segmentation: Asia

Europe

North America

ROW

Key Trends for global precision medicine software market growth This study identifies digitization of healthcare as the prime reasons driving the global precision medicine software market growth during the next few years.

Prominent vendors in global precision medicine software market We provide a detailed analysis of around 25 vendors operating in the global precision medicine software market , including some of the vendors such as F. Hoffmann-La Roche Ltd., Fabric Genomics Inc., Gene42 Inc., Human Longevity Inc., International Business Machines Corp., Koninklijke Philips NV, NantHealth Inc., Roper Technologies Inc., SOPHiA GENETICS SA and Syapse Inc. . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.Read the full report: https://www.reportlinker.com/p05873485/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original:
The Global Precision Medicine Software Market is expected to grow by USD 882.65 mn during 2020-2024, progressing at a CAGR of 11% during the forecast...

Posted in Human Longevity | Comments Off on The Global Precision Medicine Software Market is expected to grow by USD 882.65 mn during 2020-2024, progressing at a CAGR of 11% during the forecast…